Effects of Dapagliflozin on myocardial performance in non-diabetic patients with Heart failure with reduced and mid-range ejection fraction (DAPA ECHO trial)

Back

ESC Professional Premium Access

Effects of Dapagliflozin on myocardial performance in non-diabetic patients with Heart failure with reduced and mid-range ejection fraction (DAPA ECHO trial)

Session: Phenotypic approach in heart failure therapy

Topic: Pharmacotherapy

Speaker: Doctor M. Pastore (Siena, IT) Doctor A. Stefanini (Siena, IT)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speakers

Doctor Maria Concetta Pastore

University of Siena, Siena (Italy)

2 presentations

0 follower

Doctor Andrea Stefanini

University of Siena, Siena (Italy)

1 presentation

0 follower

7 more presentations in this session

In-hospital initiation of Vericiguat and short-term cardiovascular function improvement in heart failure patients with worsened renal function

Speaker: Professor J. She (Xi'an, CN)

Comparison of ventricular tachyarrhythmias in HF patients on dapagliflozin versus empagliflozin

Speaker: Doctor P. Wilson (Dallas, US)

Intermittent levosimendan infusions for advanced heart failure: a systematic review and meta-analysis of randomized controlled trials.

Speaker: Doctor M. Abouzid (Poznan, PL)

Real-world eligibility for GLP1-ra therapy in a cohort of heart failure patients

Speaker: Doctor A. Villaschi (Rozzano, IT)

Secondary erythrocytosis / polycythemia due to sodium glucose co-transporter 2 inhibitors: a real world heart failure cohort.

Speaker: Miss M. Pherai (Rotterdam, NL)

Access the full session

Phenotypic approach in heart failure therapy

Speakers: Doctor M. Pastore, Doctor A. Stefanini, Professor J. She, Doctor P. Wilson, Doctor M. Abouzid...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources